Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis

Area of Science:

• Infectious Diseases
• Cardiology
• Immunology

Background:

• Tuberculous pericarditis presents significant morbidity and mortality despite standard antituberculosis therapy.
• Evaluating adjunctive treatments is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy of adjunctive glucocorticoid therapy (prednisolone) and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis.
• To determine the impact of these interventions on a composite outcome of death, cardiac tamponade, or constrictive pericarditis.

Main Methods:

• A 2-by-2 factorial randomized controlled trial involving 1400 adults with tuberculous pericarditis.
• Participants received either prednisolone or placebo for 6 weeks, and M. indicus pranii or placebo over 3 months.
• The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis.

Main Results:

• Neither prednisolone nor M. indicus pranii significantly affected the primary composite outcome compared to placebo.
• Prednisolone significantly reduced the incidence of constrictive pericarditis and hospitalizations.
• Both interventions were associated with a significant increase in cancer incidence, primarily HIV-associated cancers.

Conclusions:

• Adjunctive prednisolone and M. indicus pranii immunotherapy did not improve the composite outcome in tuberculous pericarditis.
• Prednisolone showed a benefit in reducing constrictive pericarditis and hospitalizations, but with an increased risk of cancer.
• Further research is needed to balance benefits and risks of these therapies in specific patient populations.